Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Purpose
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
Conditions
- Castration Levels of Testosterone
- Metastatic Prostatic Adenocarcinoma
- Stage IV Prostate Cancer AJCC v8
- Stage IVA Prostate Cancer AJCC v8
- Stage IVB Prostate Cancer AJCC v8
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Sex
- Male
- Accepts Healthy Volunteers
- No
Criteria
Inclusion Criteria:
- STEP 1 REGISTRATION: DISEASE-RELATED CRITERIA: All patients must have a
histologically or cytologically proven diagnosis of adenocarcinoma of the prostate.
Patients with pure small cell carcinoma* (SCC), sarcomatoid, or squamous cell
carcinoma are not eligible. (*morphology must be consistent with SCC; synaptophysin
or chromogranin positive by immunohistochemical staining is insufficient to diagnose
SCC).
- STEP 1 REGISTRATION: DISEASE-RELATED CRITERIA: Patients must have an intact
prostate. No prior local therapy for prostate adenocarcinoma is allowed (e.g.,
brachytherapy, high-intensity focused ultrasound [HIFU], cryotherapy, laser ablative
therapies). Any prior therapy for benign conditions, such as obstruction, are
acceptable (e.g., transurethral resection of the prostate, greenlight laser
ablation, microwave ablation).
- STEP 1 REGISTRATION: DISEASE-RELATED CRITERIA: Patients must have evidence of
metastatic disease on technetium bone scan and computed tomography (CT) or magnetic
resonance imaging (MRI) within 42 days prior to starting standard systemic therapy.
Metastatic disease that is detected by positron emission tomography (PET) scan only
(sodium fluoride [NaF], prostate-specific membrane antigen [PSMA],
anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid [FACBC], carbon [C]11) but
not conventional imaging (technetium [Tc]99 bone scan, CT or MRI) or solitary
metastases by conventional imaging, must be confirmed histologically or
cytologically.
- STEP 1 REGISTRATION: DISEASE-RELATED CRITERIA: Patients with known brain metastases
are not eligible. Brain imaging studies are not required for eligibility if the
patient has no neurologic signs or symptoms suggestive of brain metastasis. If brain
imaging studies are performed, they must be negative for disease.
- STEP 1 REGISTRATION: PRIOR/CONCURRENT THERAPY CRITERIA: Patients must have received
no more than 28 weeks of standard systemic therapy (SST). SST is defined as current
National Comprehensive Cancer Network (NCCN) guidelines for metastatic prostate
cancer.
- STEP 1 REGISTRATION: PRIOR/CONCURRENT THERAPY CRITERIA: Patients must not have
progressed while on SST.
- STEP 1 REGISTRATION: PRIOR/CONCURRENT THERAPY CRITERIA: Patients with
oligometastatic prostate cancer may receive metastasis directed therapy to up to
four sites of disease prior to randomization.
- STEP 1 REGISTRATION: CLINICAL/LABORATORY CRITERIA: Patients must have a complete
physical examination and medical history within 28 days prior to registration.
- STEP 1 REGISTRATION: CLINICAL/LABORATORY CRITERIA: Patients must have a PSA
documented prior to initiation of SST and within 28 days prior to registration. Any
additional PSAs measured while receiving SST should be recorded.
- STEP 1 REGISTRATION: CLINICAL/LABORATORY CRITERIA: Patients must have a testosterone
lab documented within 28 days prior to randomization. Any additional testosterone
labs measured while receiving SST should be recorded as well as pretreatment
initiation if available.
- STEP 1 REGISTRATION: CLINICAL/LABORATORY CRITERIA: No other prior malignancy is
allowed except for the following: adequately treated basal cell or squamous cell
skin cancer, adequately treated stage 0, I or II cancer from which the patient is
currently in complete remission, or any other cancer from which the patient has been
disease free for three years.
- STEP 1 REGISTRATION: SPECIMEN SUBMISSION CRITERIA: Patients must be offered the
opportunity to participate in translational medicine studies and specimen banking
for future studies.
- STEP 1 REGISTRATION: QUALITY OF LIFE CRITERIA: Patients who can complete
Patient-Reported Outcome instruments in English, Spanish or French, must participate
in the quality of life studies.
- STEP 1 REGISTRATION: REGULATORY CRITERIA: Patients must be informed of the
investigational nature of this study and must sign and give written informed consent
in accordance with institutional and federal guidelines.
- STEP 2 RANDOMIZATION: DISEASE-RELATED CRITERIA: As a part of the OPEN registration
process the treating institution's identity is provided in order to ensure that the
current (within 365 days) date of institutional review board approval for this study
has been entered in the system.
- STEP 2 RANDOMIZATION: DISEASE-RELATED CRITERIA: Patients must have no evidence of
disease progression during the 28 weeks of SST by PSA measure, bone scan and CT or
MRI or symptomatic deterioration (as defined by physician discretion) within 28 days
prior to randomization.
- STEP 2 RANDOMIZATION: DISEASE-RELATED CRITERIA: Patients must have consultation with
a urologist and have surgically resectable disease regardless of definitive
treatment intent or randomization.
- STEP 2 RANDOMIZATION: PRIOR/CONCURRENT THERAPY CRITERIA: Patients must have received
between 22 and 28 weeks of SST as measured from the date of first hormonal therapy
or surgical castration. SST is defined by current NCCN guidelines for metastatic
prostate cancer.
- STEP 2 RANDOMIZATION: PRIOR/CONCURRENT THERAPY CRITERIA: Patients must not be
planning to receive docetaxel after randomization.
- STEP 2 RANDOMIZATION: PRIOR/CONCURRENT THERAPY CRITERIA: Any toxicities from SST
must have resolved to =< grade 1 (Common Terminology Criteria for Adverse Events
[CTCAE] version 5.0) prior to randomization.
- STEP 2 RANDOMIZATION: PRIOR/CONCURRENT THERAPY CRITERIA: Patients may have received
elective metastasis directed therapy to oligometastatic sites (=< 4 sites). All
treatment must be completed prior to randomization.
- STEP 2 RANDOMIZATION: CLINICAL/LABORATORY CRITERIA: Patients must have a PSA
performed within 28 days prior to randomization.
- STEP 2 RANDOMIZATION: CLINICAL/LABORATORY CRITERIA: Patients must have a
testosterone < 50 ng/dL within 28 days prior to randomization.
- STEP 2 RANDOMIZATION: CLINICAL/LABORATORY CRITERIA: Patients must have a Zubrod
performance status of 0 ? 1 within 28 days prior to randomization.
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Active Comparator Arm I (SST) |
Participants receive 1 acceptable form of SST as in Induction except for treatment with docetaxel and prednisone. |
|
|
Experimental Arm II (SST, prostatectomy or radiation therapy) |
Participants receive 1 acceptable form of SST as in Induction except for treatment with docetaxel and prednisone. Participants undergo prostatectomy within 8 weeks after randomization or radiation therapy within 4 weeks of randomization. |
|
|
Active Comparator Step 1 (pre-randomization) |
Standard treatment data collection prior to randomization |
|
Recruiting Locations
Gilbert 5295903, Arizona 5551752 85234
Site Public Contact
602-747-9738
Phoenix 5308655, Arizona 5551752 85004
Tucson 5318313, Arizona 5551752 85704
Site Public Contact
520-694-8900
Tucson 5318313, Arizona 5551752 85719
Little Rock 4119403, Arkansas 4099753 72205
Site Public Contact
501-686-8274
Antioch 5324200, California 5332921 94531
Clovis 5338122, California 5332921 93611
Site Public Contact
559-387-1827
Duarte 5344147, California 5332921 91010
Dublin 5344157, California 5332921 94568
Site Public Contact
877-642-4691
Fremont 5350734, California 5332921 94538
Fresno 5350937, California 5332921 93720
Fresno 5350937, California 5332921 93720
La Jolla 5363943, California 5332921 92093
Long Beach 5367929, California 5332921 90822
Site Public Contact
562-826-8000
Los Angeles 5368361, California 5332921 90033
Site Public Contact
323-865-0451
Los Angeles 5368361, California 5332921 90033
Site Public Contact
323-865-0451
Marysville 5370984, California 5332921 95901
Site Public Contact
530-749-4400
Modesto 5373900, California 5332921 95356
Oakland 5378538, California 5332921 94611
Oakland 5378538, California 5332921 94611
Palm Springs 5380668, California 5332921 92262
Site Public Contact
760-416-4730
Palo Alto 5380748, California 5332921 94304
Rancho Cordova 5385941, California 5332921 95670
Redwood City 5386834, California 5332921 94063
Richmond 5387428, California 5332921 94801
Rohnert Park 5388564, California 5332921 94928
Roseville 5388881, California 5332921 95661
Roseville 5388881, California 5332921 95678
Sacramento 5389489, California 5332921 95814
Sacramento 5389489, California 5332921 95816
Sacramento 5389489, California 5332921 95817
Site Public Contact
916-734-3089
Sacramento 5389489, California 5332921 95823
Sacramento 5389489, California 5332921 95823
San Francisco 5391959, California 5332921 94115
San Jose 5392171, California 5332921 95119
San Leandro 5392263, California 5332921 94577
San Luis Obispo 5392323, California 5332921 93401
San Rafael 5392567, California 5332921 94903
Santa Clara 5393015, California 5332921 95051
Santa Rosa 5393287, California 5332921 95403
South San Francisco 5397765, California 5332921 94080
South San Francisco 5397765, California 5332921 94080
Stockton 5399020, California 5332921 95210
Truckee 5403676, California 5332921 96161
Site Public Contact
530-582-6450
Vacaville 5405228, California 5332921 95688
Vallejo 5405380, California 5332921 94589
Walnut Creek 5406990, California 5332921 94596
Aurora 5412347, Colorado 5417618 80045
Site Public Contact
720-848-0650
Boulder 5574991, Colorado 5417618 80304
Colorado Springs 5417598, Colorado 5417618 80909
Site Public Contact
719-365-2406
Colorado Springs 5417598, Colorado 5417618 80920
Site Public Contact
719-364-6700
Denver 5419384, Colorado 5417618 80210
Edwards 5420885, Colorado 5417618 81632
Site Public Contact
970-569-7429
Fort Collins 5577147, Colorado 5417618 80524
Site Public Contact
970-297-6150
Greeley 5577592, Colorado 5417618 80631
Littleton 5429032, Colorado 5417618 80122
Loveland 5579368, Colorado 5417618 80539
Parker 5434006, Colorado 5417618 80138
Guilford 4835512, Connecticut 4831725 06437
New Haven 4839366, Connecticut 4831725 06520
Stamford 4843564, Connecticut 4831725 06904
Site Public Contact
203-323-8944
Trumbull 4844459, Connecticut 4831725 06611
Waterford 8480031, Connecticut 4831725 06385
West Haven 4845419, Connecticut 4831725 06516
Site Public Contact
203-937-3421
Newark 4143861, Delaware 4142224 19713
Newark 4143861, Delaware 4142224 19718
Washington D.C. 4140963, District of Columbia 4138106 20037
Site Public Contact
202-741-2981
Aventura 4146429, Florida 4155751 33180
Coral Gables 4151871, Florida 4155751 33146
Site Public Contact
305-243-2647
Deerfield Beach 4153071, Florida 4155751 33442
Site Public Contact
305-243-2647
Jacksonville 4160021, Florida 4155751 32207
Site Public Contact
904-202-7468
Miami 4164138, Florida 4155751 33136
Site Public Contact
305-243-2647
Miami 4164138, Florida 4155751 33176
Site Public Contact
305-243-2647
Miami Beach 4164143, Florida 4155751 33140
Plantation 4168782, Florida 4155751 33324
Site Public Contact
305-243-2647
Atlanta 4180439, Georgia 4197000 30303
Site Public Contact
404-489-9164
Atlanta 4180439, Georgia 4197000 30308
Site Public Contact
888-946-7447
Atlanta 4180439, Georgia 4197000 30322
Site Public Contact
404-778-1868
Atlanta 4180439, Georgia 4197000 30342
Site Public Contact
404-851-7115
Augusta 4180531, Georgia 4197000 30912
Decatur 4191124, Georgia 4197000 30033
Site Public Contact
404-321-6111
Caldwell 5587698, Idaho 5596512 83605
Nampa 5601933, Idaho 5596512 83687
Post Falls 5604353, Idaho 5596512 83854
Aurora 4883817, Illinois 4896861 60504
Bloomington 4885164, Illinois 4896861 61704
Canton 4831990, Illinois 4896861 61520
Carthage 4886716, Illinois 4896861 62321
Chicago 4887398, Illinois 4896861 60612
Chicago 4887398, Illinois 4896861 60612
Site Public Contact
312-355-3046
Decatur 4236895, Illinois 4896861 62526
Effingham 4237727, Illinois 4896861 62401
Eureka 4891310, Illinois 4896861 61530
Galesburg 4893392, Illinois 4896861 61401
Kewanee 4898433, Illinois 4896861 61443
Macomb 4900817, Illinois 4896861 61455
Maywood 4901514, Illinois 4896861 60153
Site Public Contact
708-226-4357
Ottawa 4905006, Illinois 4896861 61350
Pekin 4905599, Illinois 4896861 61554
Peoria 4905687, Illinois 4896861 61615
Peoria 4905687, Illinois 4896861 61636
Peoria 4905687, Illinois 4896861 61637
Peru 4905770, Illinois 4896861 61354
Princeton 4906818, Illinois 4896861 61356
Urbana 4914570, Illinois 4896861 61801
Richmond 4263681, Indiana 4921868 47374
Ames 4846834, Iowa 4862182 50010
Des Moines 4853828, Iowa 4862182 50309
Site Public Contact
515-241-6727
Iowa City 4862034, Iowa 4862182 52242
Site Public Contact
800-237-1225
Kansas City 4273837, Kansas 4273857 66160
Olathe 4276614, Kansas 4273857 66061
Overland Park 4276873, Kansas 4273857 66210
Westwood 4281639, Kansas 4273857 66205
Lexington 4297983, Kentucky 6254925 40504
Lexington 4297983, Kentucky 6254925 40509
Louisville 4299276, Kentucky 6254925 40202
Site Public Contact
502-562-3429
Metairie 4333177, Louisiana 4331987 70006
Metairie 4333177, Louisiana 4331987 70006
Bath 4957570, Maine 4971068 04530
Brewer 4959233, Maine 4971068 04412
Site Public Contact
800-987-3005
Portland 4975802, Maine 4971068 04102
Site Public Contact
207-885-7565
Sanford 4977762, Maine 4971068 04073
Site Public Contact
207-459-1600
Sanford 4977762, Maine 4971068 04073
Scarborough 4977882, Maine 4971068 04074
Ann Arbor 4984247, Michigan 5001836 48106
Ann Arbor 4984247, Michigan 5001836 48109
Site Public Contact
800-865-1125
Brighton 4986994, Michigan 5001836 48114
Brownstown, Michigan 5001836 48183
Canton 4987990, Michigan 5001836 48188
Chelsea 4988628, Michigan 5001836 48118
Clarkston 4988997, Michigan 5001836 48346
Clinton Township 4989133, Michigan 5001836 48038
Detroit 4990729, Michigan 5001836 48201
Detroit 4990729, Michigan 5001836 48202
Farmington Hills 4992523, Michigan 5001836 48334
Grand Rapids 4994358, Michigan 5001836 49503
Kalamazoo 4997787, Michigan 5001836 49007
Lansing 4998830, Michigan 5001836 48912
Site Public Contact
517-364-9400
Macomb 5000473, Michigan 5001836 48044
Madison Heights 5000500, Michigan 5001836 48071
Pontiac 5006166, Michigan 5001836 48341
Saginaw 5007989, Michigan 5001836 48601
Traverse City 5012495, Michigan 5001836 49684
Troy 5012639, Michigan 5001836 48098
West Bloomfield 7259621, Michigan 5001836 48322
Coon Rapids 5022025, Minnesota 5037779 55433
Edina 5025264, Minnesota 5037779 55435
Fridley 5027482, Minnesota 5037779 55432
Minneapolis 5037649, Minnesota 5037779 55415
Minneapolis 5037649, Minnesota 5037779 55454
Robbinsdale 5043439, Minnesota 5037779 55422
Saint Louis Park 5045021, Minnesota 5037779 55416
Saint Paul 5045360, Minnesota 5037779 55101
Shakopee 5046997, Minnesota 5037779 55379
Cape Girardeau 4379966, Missouri 4398678 63703
Cape Girardeau 4379966, Missouri 4398678 63703
Site Public Contact
573-651-5550
City of Saint Peters 4407237, Missouri 4398678 63376
Columbia 4381982, Missouri 4398678 65212
Site Public Contact
573-882-7440
Creve Coeur 4382837, Missouri 4398678 63141
Joplin 4392768, Missouri 4398678 64804
Kansas City 4393217, Missouri 4398678 64154
Rolla 4406282, Missouri 4398678 65401
Sainte Genevieve 4407294, Missouri 4398678 63670
Site Public Contact
314-996-5569
Springfield 4409896, Missouri 4398678 65804
Site Public Contact
417-269-4520
Springfield 4409896, Missouri 4398678 65807
Site Public Contact
417-269-4520
St Louis 4407066, Missouri 4398678 63110
St Louis 4407066, Missouri 4398678 63129
St Louis 4407066, Missouri 4398678 63131
Site Public Contact
314-996-5569
St Louis 4407066, Missouri 4398678 63136
St Louis 4407066, Missouri 4398678 63141
Site Public Contact
314-251-7066
Billings 5640350, Montana 5667009 59101
Bozeman 5641727, Montana 5667009 59715
Butte 5642934, Montana 5667009 59701
Site Public Contact
406-723-2621
Great Falls 5655240, Montana 5667009 59405
Kalispell 5660340, Montana 5667009 59901
Bellevue 5063805, Nebraska 5073708 68123
Omaha 5074472, Nebraska 5073708 68114
Site Public Contact
402-354-5144
Omaha 5074472, Nebraska 5073708 68118
Site Public Contact
402-559-5600
Omaha 5074472, Nebraska 5073708 68198
Henderson 5505411, Nevada 5509151 89052
Las Vegas 5506956, Nevada 5509151 89106
Las Vegas 5506956, Nevada 5509151 89128
Las Vegas 5506956, Nevada 5509151 89144
Las Vegas 5506956, Nevada 5509151 89148
Las Vegas 5506956, Nevada 5509151 89169
Concord 5084868, New Hampshire 5090174 03301
Site Public Contact
603-224-2556
Lebanon 5088597, New Hampshire 5090174 03756
Manchester 5089178, New Hampshire 5090174 03103
Site Public Contact
800-339-6484
Hackensack 5098706, New Jersey 5101760 07601
Site Public Contact
201-996-2879
Albany 5106834, New York 5128638 12208
Site Public Contact
518-262-5513
Buffalo 5110629, New York 5128638 14263
Dansville 5114492, New York 5128638 14437
Glens Falls 5118693, New York 5128638 12801
Site Public Contact
518-926-6700
New York 5128581, New York 5128638 10065
Site Public Contact
212-746-1848
Oneida 5129837, New York 5128638 13421
Oswego 5130081, New York 5128638 13126
Rochester 5134086, New York 5128638 14620
Site Public Contact
585-341-8113
Rochester 5134086, New York 5128638 14642
Site Public Contact
585-275-5830
Stony Brook 5139865, New York 5128638 11794
Site Public Contact
800-862-2215
Syracuse 5140405, New York 5128638 13210
Site Public Contact
315-464-5476
The Bronx 5110266, New York 5128638 10461
The Bronx 5110266, New York 5128638 10467
Albemarle 4452303, North Carolina 4482348 28002
Site Public Contact
800-804-9376
Charlotte 4460243, North Carolina 4482348 28203
Site Public Contact
800-804-9376
Charlotte 4460243, North Carolina 4482348 28210
Site Public Contact
980-442-2000
Charlotte 4460243, North Carolina 4482348 28262
Site Public Contact
800-804-9376
Charlotte 4460243, North Carolina 4482348 28277
Site Public Contact
800-804-9376
Concord 4461574, North Carolina 4482348 28025
Site Public Contact
800-804-9376
Gastonia 4467732, North Carolina 4482348 28054
Site Public Contact
800-804-9376
Hendersonville 4470592, North Carolina 4482348 28791
Monroe 4479946, North Carolina 4482348 28112
Site Public Contact
980-442-2000
New Bern 4481682, North Carolina 4482348 28561
Canton 5149222, Ohio 5165418 44708
Site Public Contact
888-293-4673
Centerville 4508204, Ohio 5165418 45459
Cincinnati 4508722, Ohio 5165418 45219
Cleveland 5150529, Ohio 5165418 44109
Columbus 4509177, Ohio 5165418 43210
Dayton 4509884, Ohio 5165418 45415
Kettering 4515843, Ohio 5165418 45409
Kettering 4515843, Ohio 5165418 45429
Sylvania 5173572, Ohio 5165418 43560
Toledo 5174035, Ohio 5165418 43606
West Chester 4520522, Ohio 5165418 45069
Oklahoma City 4544349, Oklahoma 4544379 73104
Chambersburg 4557109, Pennsylvania 6254927 17201
Danville 5186327, Pennsylvania 6254927 17822
Ephrata 5188815, Pennsylvania 6254927 17522
Site Public Contact
717-721-4840
Gettysburg 4558183, Pennsylvania 6254927 17325
Site Public Contact
877-441-7957
Lebanon 5197517, Pennsylvania 6254927 17042
Lewisburg 5197842, Pennsylvania 6254927 17837
Pittsburgh 5206379, Pennsylvania 6254927 15232
Site Public Contact
412-647-8073
Pittsburgh 5206379, Pennsylvania 6254927 15232
Site Public Contact
412-621-2334
Wilkes-Barre 5219488, Pennsylvania 6254927 18711
York 4562407, Pennsylvania 6254927 17403
Site Public Contact
877-441-7957
Boiling Springs 4571805, South Carolina 4597040 29316
Site Public Contact
864-241-6251
Charleston 4574324, South Carolina 4597040 29425
Greenville 4580543, South Carolina 4597040 29605
Site Public Contact
864-241-6251
Greenville 4580543, South Carolina 4597040 29607
Greenville 4580543, South Carolina 4597040 29615
Site Public Contact
864-241-6251
Greer 4580599, South Carolina 4597040 29650
Site Public Contact
864-241-6251
Myrtle Beach 4588718, South Carolina 4597040 29577
Site Public Contact
877-460-2657
Rock Hill 4593142, South Carolina 4597040 29730
Site Public Contact
800-804-9376
Rock Hill 4593142, South Carolina 4597040 29732
Site Public Contact
800-804-9376
Seneca 4595346, South Carolina 4597040 29672
Site Public Contact
864-241-6251
Nashville 4644585, Tennessee 4662168 37232
Site Public Contact
800-811-8480
Conroe 4682991, Texas 4736286 77384
Dallas 4684888, Texas 4736286 75235
Dallas 4684888, Texas 4736286 75237
Dallas 4684888, Texas 4736286 75390
Fort Worth 4691930, Texas 4736286 76104
Houston 4699066, Texas 4736286 77026-1967
Site Public Contact
713-566-5000
Houston 4699066, Texas 4736286 77030
Houston 4699066, Texas 4736286 77030
Site Public Contact
713-873-2000
Houston 4699066, Texas 4736286 77030
Houston 4699066, Texas 4736286 77030
Site Public Contact
800-553-2278
Houston 4699066, Texas 4736286 77079
League City 4705692, Texas 4736286 77573
Richardson 4722625, Texas 4736286 75080
San Antonio 4726206, Texas 4736286 78229
Site Public Contact
877-469-5300
Sugar Land 4734825, Texas 4736286 77478
Salt Lake City 5780993, Utah 5549030 84106
Salt Lake City 5780993, Utah 5549030 84112
Salt Lake City 5780993, Utah 5549030 84148
Site Public Contact
801-582-1565
Berlin Corners 5233780, Vermont 5242283 05602
Site Public Contact
802-225-5400
Burlington 5234372, Vermont 5242283 05401
Midlothian 4772943, Virginia 6254928 23114
Richmond 4781708, Virginia 6254928 23230
Richmond 4781708, Virginia 6254928 23235
Richmond 4781708, Virginia 6254928 23298
South Hill 4786619, Virginia 6254928 23970
Bellevue 5786882, Washington 5815135 98004
Site Public Contact
425-454-2148
Kirkland 5799841, Washington 5815135 98034
Site Public Contact
425-899-6000
Seattle 5809844, Washington 5815135 98109
Site Public Contact
800-804-8824
Seattle 5809844, Washington 5815135 98133
Site Public Contact
206-606-5800
Seattle 5809844, Washington 5815135 98195
Site Public Contact
800-804-8824
Morgantown 4815352, West Virginia 4826850 26506
Antigo 5244010, Wisconsin 5279468 54409
Eau Claire 5251436, Wisconsin 5279468 54701
Marshfield 5261969, Wisconsin 5279468 54449
Menomonee Falls 5262630, Wisconsin 5279468 53051
Site Public Contact
262-257-5100
Milwaukee 5263045, Wisconsin 5279468 53226
Site Public Contact
414-805-3666
Milwaukee 5263045, Wisconsin 5279468 53295
Site Public Contact
888-469-6614
Minocqua 5263156, Wisconsin 5279468 54548
New Richmond 5264475, Wisconsin 5279468 54017
Oak Creek 5265228, Wisconsin 5279468 53154
Site Public Contact
414-805-0505
Rice Lake 5268798, Wisconsin 5279468 54868
Stevens Point 5274644, Wisconsin 5279468 54481
Stevens Point 5274644, Wisconsin 5279468 54482
Wausau 5278120, Wisconsin 5279468 54401
Site Public Contact
877-405-6866
West Bend 5278422, Wisconsin 5279468 53095
Site Public Contact
414-805-0505
Weston 5278693, Wisconsin 5279468 54476
Weston 5278693, Wisconsin 5279468 54476
Wisconsin Rapids 5279436, Wisconsin 5279468 54494
Site Public Contact
715-422-7718
More Details
- NCT ID
- NCT03678025
- Status
- Recruiting
- Sponsor
- SWOG Cancer Research Network
Detailed Description
PRIMARY OBJECTIVES: I. To compare overall survival in metastatic prostate cancer patients who are randomized to standard systemic therapy (SST) plus definitive treatment of the primary tumor versus standard systemic therapy alone. SECONDARY OBJECTIVES: I. To compare overall survival in metastatic prostate cancer patients who received SST plus surgical excision of the primary tumor versus SST alone in the subset who specify the surgical intent stratification factor. II. To compare the rate of symptomatic local progression between the treatment arms. III. To compare progression-free survival (PFS) between the two treatment arms. IV. To compare rates of progression-free survival between arms for the subsets of patients with and without metastasis directed therapy (MDT) to oligometastatic sites. QUALITY OF LIFE OBJECTIVES: I. To compare between arms patient-reported urinary function and urinary bother over time (after initiation of SST at 6 months, 1, 2, and 3 years) using the Expanded Prostate Cancer Index Composite (EPIC) and patient-reported pain and physical functioning using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) between patients receiving standard systemic therapy and those receiving systemic therapy and definitive management of the primary prostate cancer. OTHER OBJECTIVES: I. To bank tissue and whole blood specimens for future use. OUTLINE: INDUCTION: Participants receive 1 of 6 acceptable forms of SST for 22-28 weeks. I. Participants undergo a bilateral orchiectomy. II. Participants receive goserelin acetate subcutaneously (SC) every 28 days or 12 weeks, histrelin acetate SC every 12 months, leuprolide acetate SC or intramuscularly (IM) every 1, 3, 4, or 6 months, and triptorelin every 1, 3, or 6 months. III. Participants receive goserelin acetate SC every 28 days or 12 weeks, histrelin acetate SC every 12 months, leuprolide acetate SC or IM every 1, 3, 4, or 6 months, and triptorelin every 1, 3, or 6 months. Participants also receive nilutamide orally (PO) daily, flutamide PO every 8 hours, and bicalutamide PO daily. IV. Participants receive degarelix via injection for 2 doses and then every 28 days. V. Participants receive nilutamide PO daily, flutamide PO every 8 hours, and bicalutamide PO daily. Participants also receive docetaxel over 1 hour every 3 weeks with or without prednisone PO every 12 hours. VI. Participants receive nilutamide PO daily, flutamide PO every 8 hours, and bicalutamide PO daily. Participants also receive abiraterone PO daily or prednisone PO every 12 hours. After completion of 22-28 weeks of SST, participants are then randomized to 1 of 2 arms. ARM I: Participants receive 1 acceptable form of SST as in Induction except for treatment with docetaxel and prednisone. ARM II: Participants receive 1 acceptable form of SST as in Induction except for treatment with docetaxel and prednisone. Participants undergo prostatectomy within 8 weeks after randomization or radiation therapy within 4 weeks of randomization. After completion of study treatment, participants are followed up for 8 years.